Sumitomo Dainippon Pharma Co., Ltd.
Basic information
- Head office
- Chief executive
- Capital
- Employees (non-consolidated)
- 4,042 people
- Employees (consolidated)
- Start date
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| JCRファーマ株式会社 | ||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
||||||||
| ポクセル社 | ||||||||
|
|
||||||||
| 株式会社ヘリオス | ||||||||
|
|
Network
History
(Meiji 30, May 14) Establishment: Osaka Seiyaku Co., Ltd. was founded in 1897 by 21 prominent pharmaceutical families in Osaka's Doushou Town.![]()
Established a pharmaceutical factory in Osaka's Ebira (formerly Osaka Factory, former Osaka General Center): Absorbed and merged with the semi-governmental and semi-private Dai Nippon Seiyaku Co., Ltd. in Tokyo, and renamed the company to Dai Nippon Seiyaku Co., Ltd.![]()
1944: Sumitomo Chemical Industry Co., Ltd. (now Sumitomo Chemical Co., Ltd.) entered the pharmaceutical business.![]()
Self-collection of thalidomide preparations (Isomin released in 1958, Provan M released in 1960): For information on the thalidomide drug disaster, see here (Sustainability 'Reliability Assurance').![]()
1984: (Showa 59) Established on February 6: Sumitomo Chemical Industry Co., Ltd.'s pharmaceutical R&D and manufacturing division and the pharmaceutical sales division of Inabata Industry Co., Ltd., which was the sole distributor of Sumitomo Chemical's drugs, were inherited. Sumitomo Pharma Co., Ltd. was established in February 1984 and began operations on October 1 of the same year. New launch of transdermal analgesic anti-inflammatory cream 'Intaban® Cream' and new launch of cephalosporin antibiotic formulation 'Sepatren®'.![]()
1985: Completion of Ehime Bio Plant: New launch of hypertension, angina, arrhythmia treatment drug 'Armal® tablets'.![]()
Established U.S. office: New release of peripheral circulation improvement agent 'Prolenar®'; new release of sustained ACE inhibitor antihypertensive 'Cetapril®'.![]()
1993: Transfer of feed additive business: New launch of hypertension, angina treatment drug 'Amrojin®'.![]()
1997: Completion of new Tokyo Product Center (now Tokyo Logistics Center): Establishment of Sumitomo Pharma UK Limited and opening of Beijing office.![]()
Opening of London and Beijing offices: New launch of gastrointestinal motility enhancer 'Gasmotin®'.![]()
1999: New launch of recombinant natural human growth hormone 'Growject®' and transfer of animal drug business: Establishment of Sumitomo Pharma America Limited.![]()
2001: New launch of antipsychotic drug 'Ruran®' : Start of sales of H2 receptor antagonist 'Tagamet®' : Commencement of operations of Sumitomo Pharma Biomedicals Co., Ltd.![]()
Closure of Osaka plant (integrated into Suzuka plant): New launch of oral cancer pain treatment solution 'Opsu®'.![]()
2003: Took over active ingredient manufacturing from Sumitomo Chemical and established a new Oita plant.![]()
Transfer of general pharmaceutical business: New launch of sustained selective H1 receptor antagonist 'Evastel® OD tablets'.![]()
News
There is no news.